Abstract
A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide. Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible. This report demonstrates that PET scintigraphy might be a helpful tool in the early diagnosis of drug-induced pulmonary toxicity.
MeSH terms
-
Administration, Oral
-
Aged
-
Antineoplastic Agents, Phytogenic / adverse effects
-
Etoposide / administration & dosage
-
Etoposide / adverse effects*
-
Fluorodeoxyglucose F18*
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Lung Diseases / chemically induced*
-
Lung Diseases / diagnostic imaging*
-
Male
-
Positron-Emission Tomography / methods*
-
Radiopharmaceuticals
-
Rare Diseases / chemically induced
-
Rare Diseases / diagnostic imaging
-
Rare Diseases / prevention & control
Substances
-
Antineoplastic Agents, Phytogenic
-
Radiopharmaceuticals
-
Fluorodeoxyglucose F18
-
Etoposide